ClinicalTrials.gg
RecruitingNCT07154134Updated Sep 4, 2025

Endocan and Copeptin Serum Levels in Preterm Neonates With Respiratory Distress Syndrome

An observational study in Endocan, Copeptin and Serum, sponsored by Tanta University. Recruiting at 1 site in Egypt. Open to participants aged 28 Weeks to 36 Weeks. Per ClinicalTrials.gov, last updated 2025-09-04.

Sponsored by Tanta University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as recruiting.
  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
40
Ages
28 Weeks to 36 Weeks
Sex
All
01

Study summary

This work aims to investigate and compare the levels of serum endocan and serum copeptin on the first day of life and correlate their levels to the severity of respiratory distress in preterm neonates suffering from respiratory distress syndrome.

Read the detailed description

Preterm birth continues to be one of the significant challenges in perinatal medicine because of its high incidence of morbidities and mortalities. Its burden on the infant, the family, healthcare systems, and society is enormous.

Endocan is implicated in the recruitment of circulating lymphocytes to inflammatory sites and leukocyte adhesion and activation. Endocan also inhibits leukocyte-endothelial cell adhesion and reduces the excessive leukocyte recruitment into the lungs.

Copeptin, also known as the arginine vasopressin (AVP) associated glycopeptides. AVP is a vasoactive neurohypophysial hormone. It is one of the primary hormones of the hypothalamic-pituitary-adrenal axis, and its primary function is to regulate water and maintain electrolyte homeostasis. The primary stimulus for AVP release is hyperosmolarity.

02

Conditions studied

  • Endocan
  • Copeptin
  • Serum
  • Preterm Neonates
  • Respiratory Distress Syndrome
03

In context

Diabetes Insipidus

191 studies on the registry are indexed under Diabetes Insipidus; 35 are open to participants now.

This study's planned enrollment of 40 is below the median of 102 across 64 observational studies indexed under Diabetes Insipidus.

Browse Diabetes Insipidus studies →

Lead sponsor

Tanta University is the lead sponsor of 1,015 studies on the registry; 321 are open to participants now.

Of its 15 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
28 Weeks to 36 Weeks
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This prospective study will be conducted at the Neonatal Intensive Care Unit (NICU), Pediatric Department, Tanta University Hospitals.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Prematurity.
  • Gestational age between 28 and 36 weeks.
  • Suffering from respiratory distress syndrome.

Exclusion criteria

Exclusion Criteria:

  • Intrauterine growth restriction (IUGR).
  • Hypoxic ischemic encephalopathy.
  • Multiple congenital anomalies.
  • Chromosomal abnormalities.
  • Preterm less than 28 weeks.
  • Neonates with a maternal history of chorioamnionitis (early sepsis).
  • Infant of diabetic mother.
  • Prelabor rupture of membranes (PROM)> 2 hours.
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
40 participants (estimated)
Patient registry
No

Groups and cohorts

  • Group I

    Neonates with gestational ages between 28 and 34 gestational weeks.

    Diagnostic Test: Serum endocan · Diagnostic Test: Serum copeptin

  • Group II

    Neonates with gestational ages between 34 and 36 gestational weeks.

    Diagnostic Test: Serum endocan · Diagnostic Test: Serum copeptin

Interventions

  • Diagnostic testSerum endocan

    Serum endocan will be measured by an enzyme-linked immunosorbent assay (ELISA) on the first day of life.

  • Diagnostic testSerum copeptin

    Serum copeptin will be measured by an enzyme-linked immunosorbent assay (ELISA) on the first day of life.

06

What researchers measure

Primary outcomes

  1. Serum endocan level for prediction of severity of respiratory distress syndrome

    Serum endocan level for prediction of severity of respiratory distress syndrome (RDS) will be recorded.

    Time frame: First day of life

Secondary outcomes

  1. Serum copeptin level for prediction of severity of respiratory distress syndrome

    Serum copeptin level for the prediction of the severity of respiratory distress syndrome (RDS) will be recorded.

    Time frame: 5th day of life

  2. Serum endocan level for prediction of mortality

    Serum endocan level for prediction of mortality will be recorded.

    Time frame: First day of life

  3. Serum copeptin level for prediction of mortality

    Serum copeptin level for prediction of mortality will be recorded.

    Time frame: 5th day of life

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The data will be available upon a reasonable request from the corresponding author after the end of study for one year.

Supporting information: Study protocol

Time frame: After the end of study for one year.

Access criteria: The data will be available upon a reasonable request from the corresponding author.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2025 (actual). Primary completion is estimated for Nov 2025, 3 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 27, 2025
First posted
Sep 4, 2025
StartActual
Jul 10, 2025
Primary completionEst.
Nov 1, 2025
CompletionEst.
Nov 1, 2025
Last update
Sep 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07154134
Lead sponsor
Tanta University
Responsible party
Asmaa Mahmoud Abdel Hamid Elmesiry (Lecturer of Pediatrics, Faculty of Medicine, Tanta University, Tanta, Egypt., Tanta University) — Principal investigator
First posted
Sep 4, 2025
Start date
Jul 10, 2025
Primary completion
Nov 1, 2025 (estimated)
Completion
Nov 1, 2025 (estimated)
Last update
Sep 4, 2025

Study contacts

Asmaa M Elmesiry, MD
Contact
asmaa.elmesery@med.tanta.edu.eg
00201224285567

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion